The IP held by Avidin and Ubichem Ltd. on the effective compounds and their applications is valuable, offering the possibility of replacing anti-TNFa treatment of patients with inflammatory diseases. The compounds exert strong anti-inflammatory action in vivo in rat Crohn-disease, arthritis and sepsis models. The compounds exert very low toxicity according to acute toxicology studies in mice.
Avidin is now starting chemical synthesis and preclinical studies of the novel chemical entities in collaboration with Ubichem Ltd.